Loratadine

Loratadine

SCHEMBL3862958

CCOC(=O)N1CCC(=C2c3ccc(Cl)cc3CCc3cccnc32)CC1.CCOC(=O)N1CCC(=C2c3ccc(Cl)cc3CCc3cccnc32)CC1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Full drug profile on Sugi Atlas →

Known targets — ChEMBL curated mechanism

HRH1

The experimentally established mechanism targets of Loratadine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HRH1 known ✓ P35367 8/20 1.00
SLC6A15 Q9H2J7 15/20 1.00
MEN1 O00255 1/20 1.00
NPC1 O15118 1/20 1.00
CACNA1F O60840 1/20 1.00
NR1I2 O75469 1/20 1.00
GMNN O75496 1/20 1.00
USP2 O75604 1/20 1.00
ABCB11 O95342 1/20 1.00
LMNA P02545 1/20 1.00
TP53 P04637 1/20 1.00
CHRM2 P08172 1/20 1.00
ABCB1 P08183 1/20 1.00
CYP3A4 P08684 1/20 1.00
ADORA3 P0DMS8 1/20 1.00
CYP2C8 P10632 1/20 1.00
CYP2D6 P10635 1/20 1.00
MAPT P10636 1/20 1.00
CYP2C9 P11712 1/20 1.00
ADRB3 P13945 1/20 1.00

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Loratadine SCHEMBL4596 1.00 SLC6A15 (1.00) SLC6A15HRH1MEN1NPC1CACNA1F
Loratadine SCHEMBL29380223 1.00 SLC6A15 (1.00) SLC6A15HRH1MEN1NPC1CACNA1F
Loratadine SCHEMBL29441811 1.00 SLC6A15 (1.00) SLC6A15HRH1MEN1NPC1CACNA1F
Loratadine SCHEMBL2166756 0.99 SLC6A15 (0.98) SLC6A15HRH1MEN1NPC1CACNA1F
Loratadine SCHEMBL21529220 0.99 SLC6A15 (0.98) SLC6A15HRH1MEN1NPC1CACNA1F
Loratadine SCHEMBL28800563 0.99 SLC6A15 (0.98) SLC6A15HRH1MEN1NPC1CACNA1F
Loratadine SCHEMBL21529200 0.99 SLC6A15 (0.98) SLC6A15HRH1MEN1NPC1CACNA1F
Loratadine SCHEMBL21529218 0.99 SLC6A15 (0.98) SLC6A15HRH1MEN1NPC1CACNA1F
Loratadine SCHEMBL28594875 0.99 SLC6A15 (0.98) SLC6A15HRH1MEN1NPC1CACNA1F
Loratadine SCHEMBL27891063 0.99 SLC6A15 (0.98) SLC6A15HRH1MEN1NPC1CACNA1F

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-110327441-A A kind of Chinese medicine line spices directly acting on body surface and preparation method 山东中医药大学第二附属医院 2019-10-15 CN disclosed
WO-2017139487-A1 METHODS, AGENTS, AND DEVICES FOR LOCAL NEUROMODULATION OF AUTONOMIC NERVES NORTHWIND MEDICAL, INC. (US) 2017-08-17 WO disclosed
CN-104547496-A Traditional Chinese medicine composition for moistening lung to arrest cough and preparation method thereof QINGDAO MUNICIPAL HOSPITAL 2015-04-29 CN disclosed
CN-104055886-A Medicinal composition for treating chronic cough, and preparation method and application thereof UNIV CHENGDU TRAD CN MEDICINE 2014-09-24 CN disclosed
CN-101596197-B Quick-release medicinal composition and preparation method thereof UNIV PLA 3RD MILITARY MEDICAL 2011-07-20 CN disclosed
CN-101596197-A Quick-release medicinal composition and preparation method thereof UNIV PLA 3RD MILITARY MEDICAL (CN) 2009-12-09 CN disclosed
EP-1670427-A4 METHODS AND REAGENTS FOR THE TREATMENT OF IMMUNOINFLAMMATORY DISORDERS COMBINATORX INC (US) 2009-01-07 EP disclosed
EP-1680121-A4 METHODS AND REAGENTS FOR THE TREATMENT OF IMMUNOINFLAMMATORY DISORDERS COMBINATORX INC (US) 2007-12-26 EP disclosed
WO-2007041584-A2 IMPLANTABLE SENSORS, IMPLANTABLE PUMPS, AND ANTI-SCARRING DRUG COMBINATIONS COMBINATORX, INCORPORATED (US) 2007-04-12 WO disclosed
WO-2007041593-A2 ANTI-SCARRING DRUG COMBINATIONS AND USE THEREOF COMBINATORX, INCORPORATED (US) 2007-04-12 WO disclosed
EP-1680121-A2 METHODS AND REAGENTS FOR THE TREATMENT OF IMMUNOINFLAMMATORY DISORDERS CombinatoRx, Incorporated (US) 2006-07-19 EP disclosed
EP-1670427-A2 METHODS AND REAGENTS FOR THE TREATMENT OF IMMUNOINFLAMMATORY DISORDERS CombinatoRx, Incorporated (US) 2006-06-21 EP disclosed
WO-2005037203-A2 METHODS AND REAGENTS FOR THE TREATMENT OF IMMUNOINFLAMMATORY DISORDERS COMBINATORX, INCORPORATED (US) 2005-04-28 WO disclosed
WO-2005027839-A2 METHODS AND REAGENTS FOR THE TREATMENT OF IMMUNOINFLAMMATORY DISORDERS COMBINATORX, INCORPORATED (US) 2005-03-31 WO disclosed
EP-1507774-A1 PROCESSES FOR PREPARATION OF POLYMORPHIC FORMS OF DESLORATADINE BIOGAL GYOGYSZERGYAR RT. (HU) 2005-02-23 EP disclosed
WO-2004108700-A1 PROCESSES FOR PREPARATION OF POLYMORPHIC FORMS OF DESLORATADINE TEVA GYOGYSZERGYAR RESZVENYTARSASAG (HU) 2004-12-16 WO disclosed
EP-1140899-A1 PROCESS FOR PREPARING TRICYCLIC COMPOUNDS HAVING ANTIHISTAMINIC ACTIVITY SCHERING CORPORATION (US) 2001-10-10 EP disclosed
WO-2000037457-A1 PROCESS FOR PREPARING TRICYCLIC COMPOUNDS HAVING ANTIHISTAMINIC ACTIVITY SCHERING CORPORATION (US) 2000-06-29 WO disclosed
US-5639798-A SLURRY REACTION OF SYNTHESIS GAS USING SELECTIVE CATALYST OF COBALT AND ZIRCONIUM ON ALUMINA YIELDS FIVE-CARBON(AND ABOVE) HYDROCARBONS WEXFORD P.A. SYNCRUDE LIMITED PARTNERSHIP (US) 1997-06-17 US disclosed
US-4042206-A Monoblock hot tops with aligned fibrous material AIKOH CO., LTD. (JA) 1977-08-16 US disclosed